1410 related articles for article (PubMed ID: 15655572)
1. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
2. The role of new agents in the treatment of colorectal cancer.
Folprecht G; Köhne CH
Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
6. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
7. [New therapy options in colorectal carcinoma].
Folprecht G; Köhne CH
Ther Umsch; 2004 Jun; 61(6):373-8. PubMed ID: 15253162
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
9. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
13. First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab.
Odabas H; Ozdemir N; Abali H; Oksuzoglu B; Isik M; Uncu D; Cihan S; Seker M; Zengin N
J BUON; 2011; 16(2):247-52. PubMed ID: 21766493
[TBL] [Abstract][Full Text] [Related]
14. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
16. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
18. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
19. [The new chemotherapy of colorectal cancers].
Taïeb J; Boige V; Ducreux M
Presse Med; 2002 Jan; 31(3):132-8. PubMed ID: 11859739
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
